Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
3
users have commented on this narrative
45
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
argenx
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
Key Takeaways Broadening indications and effective global expansion for Vyvgart, alongside pipeline progress, are driving strong, sustained revenue and margin growth. Strategic partnerships and advances in disease targeting are expanding market opportunities and operational efficiencies, supporting long-term growth potential.
View narrative
€694.75
FV
20.3% undervalued
intrinsic discount
30.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
3 days ago
author updated this narrative
GeneDx Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Expanding Pediatric Genomics Will Transform Rare Disease Diagnostics
Key Takeaways Accelerating adoption of genomics in pediatrics and enhanced AI platforms drive growth, efficiency, and margin improvement while reinforcing competitive advantage. Increasing reimbursement, enriched rare disease datasets, and global biopharma partnerships support recurring revenues, premium pricing, and high barriers to entry.
View narrative
US$115.29
FV
9.6% overvalued
intrinsic discount
19.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
19
users have followed this narrative
3 days ago
author updated this narrative
Aurora Cannabis
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Key Takeaways Strategic focus on high-margin international medical cannabis and operational efficiencies strengthens profitability, margins, and resilience against market entry barriers. Strong financial flexibility and regulatory expertise position Aurora for expansion, market consolidation, and growth without resorting to shareholder-dilutive funding.
View narrative
CA$7.93
FV
11.7% undervalued
intrinsic discount
5.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
33
users have followed this narrative
3 days ago
author updated this narrative
Gevo
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Low-Carbon Aviation And Carbon Credits Will Redefine Future Markets
Key Takeaways Rising demand for sustainable aviation fuel, carbon credits, and compliance software positions Gevo for diversified, high-margin growth and reduced revenue volatility. Proprietary technologies, major partnerships, and scalable infrastructure bolster cost competitiveness, operating leverage, and earnings potential amid increasing global decarbonization efforts.
View narrative
US$5.55
FV
67.6% undervalued
intrinsic discount
33.82%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
69
users have followed this narrative
3 days ago
author updated this narrative
ONC
BeOne Medicines
AN
AnalystConsensusTarget
Consensus Narrative from 24 Analysts
Oncology Trials And Global Expansion Will Unlock Future Markets
Key Takeaways Rapid commercial expansion and innovative therapies drive sustained growth, with a strong product pipeline supporting future revenue and margin improvement. Operational efficiencies and new product formulations position the company for enhanced profitability and resilience against external cost pressures.
View narrative
US$357.27
FV
10.1% undervalued
intrinsic discount
18.44%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
3 days ago
author updated this narrative
HubSpot
AN
AnalystConsensusTarget
Consensus Narrative from 33 Analysts
Integrated Cloud Platforms And AI Will Expand Global Reach
Key Takeaways Expansion into integrated cloud platforms, AI capabilities, and upmarket enterprise clients is driving higher recurring revenue, larger deals, and improved margins. Accelerated international growth and adaptation to evolving buyer behavior are broadening customer reach and supporting durable, long-term business expansion.
View narrative
US$695.80
FV
36.9% undervalued
intrinsic discount
17.05%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
41
users have followed this narrative
3 days ago
author updated this narrative
LifeMD
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Expanding Care Domains And Telemedicine Will Unlock New Markets
Key Takeaways Expansion into new care areas and insurance partnerships broadens market reach, reduces concentration risk, and supports stability in patient acquisition and revenue. Enhanced AI integration and the subscription-based care model improve operational efficiency, patient retention, and margin growth through automation and recurring revenue streams.
View narrative
US$12.88
FV
50.1% undervalued
intrinsic discount
14.64%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
16
users have followed this narrative
3 days ago
author updated this narrative
Toast
AN
AnalystConsensusTarget
Consensus Narrative from 24 Analysts
Integrated Digital Payments And Automation Will Unlock Future Opportunities
Key Takeaways Expanding digital solutions and automation drive increased market share, recurring revenues, and operational efficiency for restaurants upgrading from legacy systems. New market entries, product upselling, and strategic partnerships diversify revenue streams and deepen customer loyalty, boosting earnings resilience.
View narrative
US$50.33
FV
14.3% undervalued
intrinsic discount
17.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
45
users have followed this narrative
3 days ago
author updated this narrative
Iovance Biotherapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Oncology Expansion And Global Approvals Will Unlock Future Markets
Key Takeaways Expanded distribution and positive clinical data are set to boost adoption of Amtagvi and strengthen revenue growth in oncology markets. Operational streamlining, new pipeline advancements, and global expansion efforts are expected to improve profitability and diversify long-term earnings.
View narrative
US$10.00
FV
74.5% undervalued
intrinsic discount
45.56%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
59
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies